Navigation Links
Fourth IMPAKT Breast Cancer Conference
Date:4/25/2012

MEDIA ALERT

"Basic science and clinical medicine move at different pace because they follow different paths. Both however aim at improving strategies to manage cancer patients. We need to efficiently translate the good things from basic science and efficiently implement them in the clinic."

Sherene Loi and Fabrice Andr, IMPAKT 2012 Co-Chairs

IMPAKT 2012 will focus on four major areas:

  • Molecular pathology, the roots of personalized medicine beyond a microscope: emerging data confirms how valuable the role of the initial diagnosis based on the pathology report is and how this can impact treatment decisions
  • Prognostic multigene signature consensus: there is a clear need for a consensus opinion on the clinical relevance of the various prognostic signatures used by clinicians to make decisions on how to best treat patients. Top experts in the field will review the available literature and develop guidelines on how genetic signatures should be used
  • Triple negative breast cancer, a complex disease which requires intense discussions: how to improve survival of these patients with new drugs and new strategies especially after the failure of promising strategies like PARP inhibitors?
  • Tumor heterogeneity and metabolism, pathways to understand how to treat individual patients with new available targets in the era of personalized medicine: clinical implications and an open discussion on the molecular characteristics of cells with distinct phenotypes within the same tumor and on how cancer cells are metabolically rewired

Conference abstracts will be published on Wednesday, 25 April 2012 at 12:00 (CEST) and will be accessible at http://www.esmo.org/events/breast-2012-impakt/program.html

The IMPAKT 2012 Press Program will feature new study results on the following topics:

  • Breast cancer, not one disease but many
  • Mucin-1 protein and mRNA expression in breast cancer patients treated with neoadjuvant chemotherapy
  • Independent blinded validation of the genomic index of Sensitivity to Endocrine Therapy (SET)
  • The role of AP-1 in endocrine-resistant breast cancer
  • Advances in breast cancer research help choose the right treatment for the right patient
  • Gene modules and pathological complete response to neoadjuvant chemotherapy in breast cancer: a pooled analysis
  • Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically-defined Luminal A breast cancer
  • Translational studies within the TAMRAD randomized GINECO trial: Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer
  • Breast cancer in young women is a biologically unique disease that requires customized management strategies

Highlights on:

  • Challenges, clinical perspectives and implications for biomarker and drug development
  • Making personalized medicine a reality for breast cancer patients: how to speed up the path for reimbursement
  • Intratumor heterogeneity: a challenge for personalized medicine? Can next generation sequencing help solve the problem?
  • Towards a further segmentation of triple negative breast cancer?
  • Can gene signatures become a standard procedure for daily practice? What's new to predict outcome and drug sensitivity?

Press conference

Thursday, 3 May 2012, 11:00-12:00 (CEST)

Hosts:

Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder

Fabrice Andr, Institut de Cancrologie Gustave Roussy, Breast cancer Unit, Department of Medical Oncology, Villejuif, France, IMPAKT2012 Scientific Chair

Sherene Loi, Institute Jules Bordet, Breast International Group (BIG), Brussels, Belgium, IMPAKT2012 Executive Chair

The press conference will highlight the latest advances in breast cancer research that can help improve treatment strategies for breast cancer patients.

The panel features world's leading breast cancer experts.


'/>"/>
Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008
2. BIO-key(R) Announces Fourth Quarter and 2008 Year-End Earnings Release and Conference Call Schedule
3. Aware, Inc. Reports Fourth Quarter and 2008 Financial Results
4. BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008
5. Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results
6. BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability
7. MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results
8. AACR hosts Fourth Annual Science of Cancer Health Disparities Conference
9. Modern genetics answers age-old question on Garrods fourth inborn error of metabolism
10. Aware, Inc. Reports Fourth Quarter and 2011 Financial Results
11. IMPAKT -- Breast cancer conference highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth management ... The Future of San Diego Life Science event at the Estancia La Jolla Resort ... the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and ...
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of $0.24 per share ... stockholders of record as of the close of business on ... approval of the Board of Directors and may be adjusted ...
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute , ... the winners for the 2015 Foresight Institute Feynman Prizes. , These prestigious ... categories, one for experiment and the other for theory in nanotechnology. Prof. Markus ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A ... offer a new way to treat the disease. Surviving Mesothelioma has just posted an ... Scientists from several Korean institutions based their mesothelioma study on the fact the Manumycin ...
Breaking Biology Technology: